China Pharma Valuation
| CPHI Stock | USD 0.24 0.04 14.29% |
China Pharma seems to be fairly valued based on Macroaxis valuation methodology. Our model approximates the value of China Pharma Holdings from analyzing the firm fundamentals such as Return On Equity of -0.75, current valuation of 7.83 M, and Profit Margin of (0.70) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that China Pharma's price fluctuation is out of control at this time. Calculation of the real value of China Pharma Holdings is based on 3 months time horizon. Increasing China Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since China Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of China Stock. However, China Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.24 | Real 0.24 | Hype 0.24 | Naive 0.26 |
The intrinsic value of China Pharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence China Pharma's stock price.
Estimating the potential upside or downside of China Pharma Holdings helps investors to forecast how China stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of China Pharma more accurately as focusing exclusively on China Pharma's fundamentals will not take into account other important factors: China Pharma Total Value Analysis
China Pharma Holdings is currently forecasted to have valuation of 7.83 M with market capitalization of 3.69 M, debt of 4.63 M, and cash on hands of 2.24 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the China Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.83 M | 3.69 M | 4.63 M | 2.24 M |
China Pharma Investor Information
About 51.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. China Pharma Holdings recorded a loss per share of 0.69. The entity had not issued any dividends in recent years. The firm had 1:5 split on the 6th of March 2024. Based on the key measurements obtained from China Pharma's financial statements, China Pharma Holdings is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.China Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. China Pharma has an asset utilization ratio of 42.57 percent. This signifies that the Company is making $0.43 for each dollar of assets. An increasing asset utilization means that China Pharma Holdings is more efficient with each dollar of assets it utilizes for everyday operations.China Pharma Ownership Allocation
China Pharma holds a total of 19.25 Million outstanding shares. China Pharma Holdings retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.China Pharma Profitability Analysis
The company reported the previous year's revenue of 7.01 M. Net Loss for the year was (3.08 M) with profit before overhead, payroll, taxes, and interest of 349.27 K.About China Pharma Valuation
An absolute valuation paradigm, as applied to China Stock, attempts to find the value of China Pharma Holdings based on its fundamental and basic technical indicators. By analyzing China Pharma's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of China Pharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of China Pharma. We calculate exposure to China Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of China Pharma's related companies.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the Peoples Republic of China. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the Peoples Republic of China. China Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 236 people.
China Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 3.4 M |
Complementary Tools for China Stock analysis
When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |